ADDED
As of March 18, 2026, 36,632,775 shares of the Registrant s common stock were outstanding.
BUSINESS Overview We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.
We are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered bacteriophages with our proprietary phage-specific host-engineered cGMP manufacturing capabilities to advance a clinical pipeline of high-quality bacteriophage product candidates.
We believe that we are uniquely advancing two distinct clinical candidates, referred to as AP-PA02 and AP-SA02, targeting two different bacterial pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection as well as acute systemic bacterial infection.
To date, we have completed three critical Phase 2 randomized, double-blind, placebo controlled clinical trials.
We have combined our clinical data with rigorous and innovative in vitro science to extend our knowledge of phage biology enabling continued enhancement of in vivo phage function.
Importantly, we have improved our manufacturing processes, which significantly increases phage titers and purity, and improves production efficiency.
Aligned with these improvements, we have been able to reproducibly produce high titer and high purity phages with lot-to-lot consistency, configuring our phage platform for full commercialization with the goal of ensuring commercial viability of our current and future phage product candidates across a variety of potential use cases.
Pseudomonas aeruginosa Phage Product Candidate, AP-PA02 Clinical Development of AP-PA02 in Cystic Fibrosis: Completed Phase 1b/2a Study Our first phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa ( P.
This study was supported by the CFF, which granted us a Therapeutics Development Award of $5.0 million.
REMOVED
As of February 28, 2025, 36,183,067 shares of the Registrant s common stock were outstanding.
This Annual Report includes trademarks and registered trademarks of Armata Pharmaceuticals, Inc.
BUSINESS Overview We are a clinical-stage biotechnology company having completed three Phase 2 trials focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.
We have completed three critical Phase 2 trials, utilizing two distinct phage cocktails against two different bacterial pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection, as well as acute systemic bacterial infection.
We believe we are on a critical pathway towards pivotal Phase 3 clinical studies.
We are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered (synthetic) bacteriophages with our proprietary phage-specific host-engineered current good manufacturing practice ( cGMP ) manufacturing capabilities to advance a target pipeline of high-quality bacteriophage product candidates for late-stage clinical development.
We have improved our manufacturing processes by significantly increasing phage titers and improving production efficiency with the goal of ensuring commercial viability.
We believe that we are uniquely advancing two lead candidates, referred to as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections.
Our first lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa ( P.
On October 14, 2020, we received the approval to proceed from the U.S.